Anemia and thrombocytopenia
Education on Anemia and thrombocytopenia and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Anemia and thrombocytopenia and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Anemia and thrombocytopenia?
Anemia and thrombocytopenia is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Hematologic conditions involve blood cells and bone marrow. The patent discusses marrow health and neutrophil balance.
What Mark Egly's patent discusses
Iron deficiency anemia is a condition in which blood lacks adequate healthy red blood cells, which carry oxygen to the body's tissues. Iron deficiency anemia occurs due to insufficient iron. Iron deficiency anemia may leave the patient tired and short of breath. Aplastic anemia is a condition that occurs when a patient's body stops producing enough new blood cells. The condition leaves the patient fatigued and more prone to infections and uncontrolled bleeding. Thrombocytopenia is a condition characterized by a low blood platelet count. Platelets, also called thrombocytes, are colorless blood cells that help blood clot. Platelets stop bleeding by clumping and forming plugs in blood vessel injuries. Thrombocytopenia often occurs because of a separate disorder, such as leukemia or an immune system problem, or it can be a side effect of taking certain medications. In one embodiment, AAT may be used to treat, control, or prevent anemia and thrombocytopenia in patients, either with or without known AATD. A diagnosis of anemia or thrombocytopenia may prompt a medical provider to test a patient for AATD. Alternatively, a patient diagnosed with anemia or thrombocytopenia may seek genetic…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Anemia and thrombocytopenia, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Anemia and thrombocytopenia, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: